Trytosaveabit commented on a stock · Oct 27, 2023 06:05

News

$Kymera Therapeutics (KYMR.US)$ Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
4 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

6947 Views

Comment

Trytosaveabit

3611Followers

23Following

53KVisitors